How effective is Paxlovid in reducing the severity of COVID-19 symptoms?

Zenodo (CERN European Organization for Nuclear Research) 2026 Open access

Read full text
Authors: Tripdatabase
DOI: 10.5281/zenodo.18305701
Cited by: 0

Abstract

Paxlovid is effective in reducing the risk of severe COVID-19 outcomes such as hospitalization and death, particularly in high-risk patients. Evidence is less clear regarding its benefits in vaccinated or lower-risk populations.

Fields of Study & Subjects

COVID-19 Clinical Research Studies SARS-CoV-2 and COVID-19 Research Respiratory viral infections research

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
19 January 2026